Sugi Predict

Sugi Predict / Compounds / SCHEMBL842440

SCHEMBL842440

SCHEMBL842440

Nc1ncnc2nc(Cl)[nH]c12

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADORA2A P29274 1/20 0.61
▸ ADORA1 P30542 1/20 0.61
▸ NUDT1 P36639 2/20 0.56
▸ LMNA P02545 3/20 0.55
▸ TSHR P16473 1/20 0.55
▸ PI4KA P42356 8/20 0.53
▸ PI4K2B Q8TCG2 8/20 0.53
▸ PI4K2A Q9BTU6 8/20 0.53
▸ PI4KB Q9UBF8 8/20 0.53
▸ ERBB2 P04626 1/20 0.53
▸ HSP90AA1 P07900 1/20 0.53
▸ HSP90AB1 P08238 1/20 0.53
▸ DRD3 P35462 1/20 0.47
▸ XDH P47989 1/20 0.47
▸ LRRK2 Q5S007 1/20 0.47
▸ HPGD P15428 1/20 0.46
▸ HTT P42858 1/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.46
▸ APEX1 P27695 1/20 0.44
▸ ALDH1A1 P00352 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29904248 1.00 ADORA2A (0.61) ADORA2AADORA1NUDT1LMNATSHR
SCHEMBL6016629 0.79 EGLN1 (0.43) ADORA2AADORA1NUDT1LMNATSHR
SCHEMBL29400753 0.79 ADORA2A (0.66) ADORA2AADORA1NUDT1LMNATSHR
SCHEMBL42314 0.79 ADORA2A (0.66) ADORA2AADORA1NUDT1LMNATSHR
SCHEMBL30109321 0.78 NUDT1 (0.68) ADORA2AADORA1NUDT1LMNATSHR
SCHEMBL1059581 0.78 NUDT1 (0.68) ADORA2AADORA1NUDT1LMNATSHR
SCHEMBL843169 0.76 ADORA2A (0.61) ADORA2AADORA1NUDT1LMNATSHR
SCHEMBL31096978 0.76 ADORA2A (0.61) ADORA2AADORA1NUDT1LMNATSHR
SCHEMBL842891 0.76 ADORA2A (0.61) ADORA2AADORA1NUDT1LMNATSHR
SCHEMBL42335 0.76 ADORA2A (0.61) ADORA2AADORA1NUDT1LMNATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 246 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122029176-A Containing a plurality of oligonucleotides modified oligonucleotides 阿达尔克斯制药有限公司 2026-05-12 — — CN claimed
CN-122028913-A Oligonucleotides containing ligands in nucleobases, 2 'or 3' positions 阿达尔克斯制药有限公司 2026-05-12 — — CN claimed
CN-122029177-A Oligonucleotides containing multiple ligands and/or lipids 阿达尔克斯制药有限公司 2026-05-12 — — CN claimed
US-20250257360-A1 OLIGONUCLEOTIDE INTERFERENCE TREATMENTS OF PROSTATE CANCER UNIV OKLAHOMA (US) 2025-08-14 — — US claimed
CN-113151261-B Antisense oligonucleotides as inhibitors of TGF-R signaling 神经视觉医药有限公司 2025-06-17 — — CN claimed
WO-2025111452-A2 CHEMICAL MODIFICATIONS IN PEgRNA and ngRNAs PRIME MEDICINE, INC. (US) 2025-05-30 — — WO claimed
WO-2025111430-A1 CHEMICAL MODIFICATIONS IN mRNA POLY(A) TAIL PRIME MEDICINE, INC. (US) 2025-05-30 — — WO claimed
WO-2025043082-A2 COMPOSITIONS AND METHODS TO IMPROVE RNA PROPERTIES USING BASE, PHOSPHODIESTER LINKAGE, SUGAR BACKBONE, AND CAP MODIFICATIONS THE BROAD INSTITUTE, INC. (US) 2025-02-27 — — WO claimed
WO-2025038960-A1 OLIGONUCLEOTIDES CONTAINING A LIGAND AT AN INTERNAL POSITION ADARX PHARMACEUTICALS, INC. (US) 2025-02-20 — — WO claimed
WO-2025038971-A1 OLIGONUCLEOTIDES CONTAINING A LIGAND AT A NUCLEOBASE, 2' POSITION, OR 3' POSITION ADARX PHARMACEUTICALS, INC. (US) 2025-02-20 — — WO claimed
US-20170319614-A1 ANTISENSE-OLIGONUCLEOTIDES AS INHIBITORS OF TGF-R SIGNALING Neurovision Pharma GmbH (DE) 2017-11-09 — — US claimed
EP-3218488-A1 ANTISENSE-OLIGONUCLEOTIDES AS INHIBITORS OF TGF-R SIGNALING Neurovision Pharma GmbH (DE) 2017-09-20 — — EP claimed
CN-107002082-A Antisense oligonucleotides as inhibitors of TGF-R signaling 神经视觉医药有限公司 2017-08-01 — — CN claimed
WO-2016075339-A1 ANTISENSE-OLIGONUCLEOTIDES AS INHIBITORS OF TGF-R SIGNALING Neurovision Pharma GmbH (DE) 2016-05-19 — — WO claimed
US-20160138029-A1 ANTISENSE-OLIGONUCLEOTIDES AS INHIBITORS OF TGF-R SIGNALING Neurovision Pharma GmbH (DE) 2016-05-19 — — US claimed
EP-0898575-B1 A COMBINATORIAL PROTECTING GROUP STRATEGY FOR MULTIFUNCTIONAL MOLECULES KOESTER HUBERT DR (US) 2004-12-29 — — EP claimed
US-20030194741-A1 COMBINATORIAL PROTECTING GROUP STRATEGY FOR MULTIFUNCTIONAL MOLECULES CAPROTEC BIOANALYTICS GMBH (DE) 2003-10-16 — — US claimed
US-20030054410-A1 Combinatorial protecting group strategy for multifunctional molecules CAPROTEC BIOANALYTICS GMBH (DE) 2003-03-20 — — US claimed
EP-0898575-A2 A COMBINATORIAL PROTECTING GROUP STRATEGY FOR MULTIFUNCTIONAL MOLECULES KÖSTER, Hubert (US) 1999-03-03 — — EP claimed
WO-1997041139-A2 A COMBINATORIAL PROTECTING GROUP STRATEGY FOR MULTIFUNCTIONAL MOLECULES KOESTER HUBERT (US) 1997-11-06 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030194741-A1 COMBINATORIAL PROTECTING GROUP STRATEGY FOR MULTIFUNCTIONAL MOLECULES ADAR, RNMT, ATIC ADORA2A 113/4885ADORA1 242/4885NUDT1 264/4885
US-20170319614-A1 ANTISENSE-OLIGONUCLEOTIDES AS INHIBITORS OF TGF-R SIGNALING TGFBR1, TGFBR2, TGFB1 ADORA2A 1258/4885ADORA1 689/4885NUDT1 335/4885
US-20030054410-A1 Combinatorial protecting group strategy for multifunctional molecules ADAR, RNMT, RRM1 ADORA2A 123/4885ADORA1 217/4885NUDT1 251/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.